Akkermansia muciniphila colonizes the mucosal layer of the human gut. It is particularly effective at increasing mucus thickness and improving barrier function. A. muciniphila restores mucus layer thickness; its extracellular vesicles also reduce intestinal permeability by controlling tight junctions.
A subtle but important nuance: A. muciniphila *consumes* mucin — that is part of the mechanism. Deficiency of Akkermansia and mucin depletion are linked to barrier dysfunction and inflammation, while excessive mucin consumption can damage the barrier. Balance matters.
Contrast with R. gnavus: R. gnavus is also a mucin-degrader, but with opposite consequence. It is common in 90%+ of humans but blooms in IBD. Multiple studies link its overabundance with inflammatory bowel disease. R. gnavus produces an inflammatory polysaccharide — a plausible molecular mechanism connecting microbiome composition to inflammation.
Both eat mucin. Akkermansia stimulates goblet cells to produce more good mucus. R. gnavus releases sialic acid that fuels other pathogens and produces pro-inflammatory polysaccharides. The question is not whether mucin is being degraded; it is who is degrading it and what they do with the byproducts.
Measurement: shotgun metagenomic stool analysis (not just 16S) — available via GA-map (Bio-Me, Oslo), Sun Genomics, or research-grade analyses at DTU and major hospitals.